Britain backs GSK`s gene therapy for `bubble boy` syndrome

Published 8y ago

GlaxoSmithKline's gene therapy for the so-called "bubble boy" disease was approved by Britain's healthcare cost watchdog NICE, despite a price tag of almost 600,000 euros ($700,000). More »